Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RC28-E in Wet Age-Related Macular Degeneration
NCT04270669Phase 2Completed
- Sponsor
- RemeGen
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflimrufusp alfa in exudative macular degeneration, sponsored by RemeGen. Started Apr 2020; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04270669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270669.